Supriya Lifescience Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Supriya Lifescience reported a 16.4% YoY revenue increase, with EBITDA and PAT exceeding estimates. Analysts revised EPS estimates upward, maintaining a BUY rating with a target price of INR 843.

Supriya Lifescience Maintains BUY Rating with Target Price - 03 Jun, 2025

Supriya Lifescience anticipates over 20% annual revenue growth, driven by new product launches and a strong operational performance. Q4FY25 revenue rose 16.4%, with profit after tax up 36.4%. The company expects margins to stabilize between 33% and 35%. A new 10-year API supply contract is projected to add ₹60-70 crore annually at peak. The focus remains on expanding its anaesthetic and specialty therapies portfolio.

Supriya Lifescience Projects Strong Revenue Growth - 28 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 year, SUPRIYA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 1 year, SUPRIYA stock has moved up by 91.2%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Foreign Institutions have increased holdings from 6.52% to 7.19% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

Promoters holdings remained unchanged at 68.30% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor holdings remained unchanged at 20.26% of holdings in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Unchanged

In the last 3 years, Torrent Pharmaceuticals Ltd has given 126.1% return, outperforming this stock by 30.5%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Mutual Funds have decreased holdings from 0.67% to 0.66% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

BSE Healthcare

BSE Small-Cap

ITI Large & Mid Cap Fund Direct Growth

ITI ELSS Tax Saver Fund Direct Growth

Motilal Oswal Nifty Microcap 250 Index Fund Direct Growth

Quantum Small Cap Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

Supriya Lifescience Ltd’s net profit jumped 36.42% since last year same period to ₹50.38Cr in the Q4 2024-2025. On a quarterly growth basis, Supriya Lifescience Ltd has generated 7.7% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-1.07	Bearish
CCI (20)	50.47	Neutral
RSI (14)	37	Neutral
Momentum (10)	-2.3	Bearish
ADI (14)	23.01	Neutral
Ultimate Oscillator (7,14,28)	27.94	Bearish

Name	Value	Action
SMA (20)	690.92	Bearish
EMA (20)	690.65	Bearish
VWMA (20)	690.22	Bearish
SMA (50)	692.59	Bearish
EMA (50)	692.11	Bearish
SMA (200)	694.96	Bearish
EMA (200)	693.98	Bearish
KAMA (200)	692.68	Bearish
DEMA (200)	693.02	Bearish

Supriya Lifescience Ltd (SUPRIYA)

Summary

Overall

Oscillators

Moving Averages